

IPW

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Oron YACOBY-ZEEVI, et al

Serial No.: 10/645,659

Filed: 22 August 2003

For: HEPARANASE ACTIVITY  
NEUTRALIZING ANTI-  
HEPARANASE MONOCLONAL...

Examiner:

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450



Group Art Unit: 1635

Attorney  
Docket: 26128

**INFORMATION DISCLOSURE STATEMENT**

Sir:


Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This is a continuation in part of U.S. Patent Application No. 10/368,044, filed February 19, 2003, which also claims priority as a continuation from U.S. Patent Application No. 09/186,200, filed November 4, 1998, now U.S. Patent No. 6,562,950, issued May 13, 2003, which is a continuation-in-part of U.S. Patent Application No. 09/071,739, filed May 1, 1998, now U.S. Patent No. 6,177,545, issued January 23, 2001, which is a continuation-in-part of U.S. Patent Application No. 08/922,170, filed September 2, 1997, now U.S. Patent No. 5,968,822, issued October 19, 1999. This application also claims priority from U.S. Patent Application No. 10/456,573, filed June 9, 2003, which is a continuation-in-part of U.S. Patent Application No. 09/435,739, filed November 8, 1999, which is a continuation of U.S. Patent Application No. 09/258,892, filed March 1, 1999,

now expired, which is a continuation-in-part of PCT Application No. PCT/US98/17954, filed August 31, 1998, now expired..

Applicant requests that MPEP 609 be complied with and the examiner consider information which has been considered by the Office in a parent application when examining (A) a continuation application, (B) a divisional application, or (C) a continuation-in-part application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,  
  
Sol Shreibein  
Registration No. 25,457

Date: November 10, 2004



PTO/SB/08A (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Complete if Known**

|                    |            |
|--------------------|------------|
| Application Number | 10/645,659 |
|--------------------|------------|

|             |            |
|-------------|------------|
| Filing Date | 08/22/2003 |
|-------------|------------|

|                      |              |
|----------------------|--------------|
| First Named Inventor | YACOBY-ZEEVI |
|----------------------|--------------|

|                |      |
|----------------|------|
| Group Art Unit | 1635 |
|----------------|------|

|               |                    |
|---------------|--------------------|
| Examiner Name | /Marianne Dibrind/ |
|---------------|--------------------|

|       |   |    |   |                        |       |
|-------|---|----|---|------------------------|-------|
| Sheet | 1 | Of | 1 | Attorney Docket Number | 26128 |
|-------|---|----|---|------------------------|-------|

Examiner  
InitialsCite  
No. 1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

 $T^2$ 

MDA

Fairbanks et al, "Processing of the Human Heparanase Precursor and Evidence that the Active Enzyme is a Heterodimer", *J. Biol. Chem.*, vol. 274, No. 42, pp. 29587-29590, 15 Oct. 1999.

/MD/

Hulett et al, "Cloning of Mammalian Heparanase, an Important Enzyme in Tumor Invasion and Metastasis". *Nature Medicine*. 5(7):803-809. 1999

/MD/

Toyoshima et al, "Human Heparanase: Purification, Characterization, Cloning, and Expression", *J. of Biolog. Chemistry*, vol. 274, No. 34, pp. 24153-24160, 20 Aug. 1999.

MD/

Miao et al, "Cloning, Expression, and Purification of Mouse Heparanase", *Protein Expression and Purification*, 26:425-431, 2002

/MD/

Freeman et al, "Human Platelet Heparanase: Purification, Characterization and Catalytic Activity", *Biochem J.* 330(3): 1341-1350, 1998.

Examiner  
Signature

/Marianne Dibrino/

Date  
Considered

03/04/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>. Unique citation designation number. <sup>2</sup>. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.